Midsize Pharmaceutical Firms Bet on Smart Innovation 'Three-Pronged Strategy'…AI, Environmental Tech, National Policy

Midsize pharmaceutical companies are accelerating smart innovation initiatives to strengthen cost competitiveness and address labor shortages in local manufacturing sites. Each firm is adopting tailored, cost-effective strategies to overcome limited investment constraints. Han Dok is focusing on government-supported national projects, securing a unique spot in the 2026 AI application acceleration program with a 42 billion won investment to build an AI-driven production system. Youuji Pharmaceutical is implementing AI-driven process improvements without major capital investments, while Guangdong Pharmaceutical is transitioning to eco-friendly equipment to reduce manufacturing costs. All firms aim to achieve productivity gains and cost advantages through differentiated smart innovation approaches.